Heron Therapeutics Inc vs Marathon Petroleum Corp — how do they compare? Heron Therapeutics Inc trades at $0.37 (market cap $68.01M), while Marathon Petroleum Corp trades at $461.46 (market cap $130.12B). The key difference: Marathon Petroleum Corp is far larger — about 1913.2× Heron Therapeutics Inc's market cap, and Marathon Petroleum Corp pays a 0.86% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Heron Therapeutics Inc for 35 Days and Marathon Petroleum Corp for 54 Days on average.
| HRTX | MPC | |
|---|---|---|
Market Cap | $68.01M | $130.12B |
Volume | 1,891,941 | 2,749,647 |
Sector | Health | Energy |
52-Week High | $1.49 | $463.34 |
52-Week Low | $0.27 | $162.63 |
Typical Hold Time | 35 Days | 54 Days |
Enterprise Value | $174.75M | $156.64B |
Dividend Yield | — | 0.86% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) is trading at $0.39, up 17.58% today, with a bullish technical outlook from moving averages but mixed signals from oscillators. The company maintains strong gross margins of 70.07% but continues to report net losses, with Q2 2026 missing both EPS and revenue expectations. Analyst sentiment remains overwhelmingly positive with 89% buy ratings despite recent earnings disappointments and negative profitability metrics.
While analyst consensus is strongly bullish, HRTX faces significant fundamental challenges including consistent net losses, negative ROE of -78.72%, and cash flow concerns. The stock's current momentum appears driven by technical factors rather than improving fundamentals, creating a high-risk investment profile that requires careful monitoring of upcoming Q3 earnings and revenue stabilization efforts.
Marathon Petroleum (MPC) trades at $442.26, up 2.29% with strong technical momentum and bullish moving average signals. The stock shows robust fundamentals with a P/E of 15.33, ROE of 47.9%, and consistent earnings beats in recent quarters. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export restrictions pose headwinds. Technical indicators show the stock trading near pivot point resistance at $442 with RSI suggesting potential overbought conditions.
MPC presents a compelling value opportunity with attractive valuation metrics and strong profitability, though investors face risks from potential regulatory changes and volatile energy markets. Analyst consensus remains strongly bullish with 76% buy ratings and a $420.30 price target, suggesting modest downside from current levels. The company's solid cash flow generation and dividend payments provide shareholder returns support.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →